62.25 -0.40 (-0.64%)
Pre-market: 5:10AM EST
|Bid||61.20 x 1200|
|Ask||63.79 x 1300|
|Day's range||62.55 - 65.20|
|52-week range||51.72 - 77.03|
|Beta (5Y monthly)||0.90|
|PE ratio (TTM)||12.33|
|Earnings date||28 Apr 2020 - 03 May 2020|
|Forward dividend & yield||2.00 (3.11%)|
|Ex-dividend date||21 Jan 2020|
|1y target est||84.25|
Oscar Health is offering prescription drugs at rock-bottom prices, following the lead of other health care players responding to the public’s demand for lower costs.
One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.
As you might know, CVS Health Corporation (NYSE:CVS) recently reported its annual numbers. Results were roughly in...
(Bloomberg) -- CVS Health Corp. shook up its senior management ranks, putting a company veteran in charge of its pharmacy-benefit management business, less than two years after bringing on a longtime pharmaceutical executive to run it.The company said in a statement Wednesday that Alan Lotvin had been named president of CVS Caremark, taking the reins from Derica Rice, who will depart CVS. Rice, a former Eli Lilly & Co. executive who joined the company in 2018, will remain through this month to help ensure a smooth transition.The move puts one of Chief Executive Officer Larry Merlo’s most trusted lieutenants at the helm of CVS’s largest division. Lotvin has been with CVS since 2012, and in recent years had been charged with transforming the company after it acquired Aetna for $67 billion in its largest-ever takeover.Rice’s departure had been in the works for “some time” before the announcement, Merlo said in an interview. Merlo said the role of CVS’s pharmacy-services business is changing and Lotvin has “deep experience” in the space.The change reflects “the deep and talented bench that’s resonant within CVS Health,” Merlo said. “Quite frankly, I think that’s the story here, the talent that’s resonant across the organization.”The Aetna deal was premised in part on the idea that CVS could transform its drugstores into centers where patients could receive basic care and pick up prescriptions, driving down health costs. But CVS shares have languished since the transaction closed in late 2018, with investors wary of the effects of political wrangling over drug prices, as well as the overall growth prospects of the combined company.Rice’s departure followed news last week that former Aetna CEO Mark Bertolini had stepped down from CVS’s board. Bertolini said he had offered to remain a director past his current term, but wasn’t renominated. And Kevin Hourican, who led CVS’s retail-pharmacy business, left last month to become CEO of food-service company Sysco. Hourican joined CVS in 2012 from Macy’s.Other notable Aetna alumni have also departed recently, including former Chief Technology Officer Claus Torp Jensen, who left for Memorial Sloan Kettering in October. But some of the insurer’s most visible leaders remain, including Karen Lynch, who is president of the business, and Rick Jelinek, who’s leading the integration. And CVS said Wednesday it promoted Aetna’s Jonathan Mayhew to executive vice president of transformation, a role previously occupied by Lotvin.“As you look at talent within the organization, the Aetna operating team is largely intact, so there has not been a large exodus of the company,” Merlo said. “I’m very pleased with how the two organizations and the culture of the organizations is coming together.”Shares of CVS were down 1.2% at $72.94 at 2:10 p.m. in New York.The company also projected better-than-expected revenue for the year and posted stronger-than-forecast fourth-quarter results. In an investor presentation, CVS said it expects 2020 revenue of $261.97 billion to $265.48 billion, above the average Wall Street forecast of $256.89 billion. The pharmacy-services business is expected to be a critical plank of that growth, with projected 2020 sales of $137.50 billion to $139.45 billion.To contact the reporter on this story: Angelica LaVito in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Drew Armstrong at email@example.com, Timothy AnnettFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
The company, which acquired health insurer Aetna for $69 billion in 2018, is not planning further major deals until it has completed the Aetna integration and reduced the debt load it took on, Chief Executive Larry Merlo told Reuters in an interview. Aetna revenue nearly tripled in the quarter from a year ago to $17.15 billion.
Shopify (SHOP) impressed investors with a big beat on both top and bottom lines: 43 cents per share versus 23 cents expected, on $505.2 million which easily surpassed the Zacks consensus $482.3 million.
CVS Health (CVS) delivered earnings and revenue surprises of 2.98% and 4.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Investing.com - CVS Health Corp reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Federal Reserve Chairman Jay Powell heads to Capitol Hill for another day of testimony in front of Congress and Cisco reports earnings Wednesday.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amid surging health care costs and acrimonious public debate, a new study found that a public-run system would save money over time.
Dividend paying stocks like CVS Health Corporation (NYSE:CVS) tend to be popular with investors, and for good reason...